Quarterly ResultMay 11, 2026, 04:20 PM
Aura Biosciences Q1 Net Loss $33.68M; R&D Expenses Rise
AI Summary
Aura Biosciences reported a net loss of $33.68 million for the three months ended March 31, 2026, an increase from $27.48 million in the same period last year. Research and development expenses rose to $27.96 million. Subsequent to the quarter-end, the company successfully completed a follow-on offering, raising approximately $280.8 million in net proceeds, which alleviated previous substantial doubt about its ability to continue as a going concern.
Key Highlights
- Net loss for Q1 2026 was $33.68 million, compared to $27.48 million in Q1 2025.
- Research and development expenses increased to $27.96 million in Q1 2026 from $23.34 million in Q1 2025.
- Cash and cash equivalents stood at $84.79 million as of March 31, 2026.
- Total assets were $137.68 million and total liabilities were $30.43 million at quarter-end.
- Net loss per common share was $0.50 for Q1 2026.
- Subsequent to quarter-end, the company raised $280.8 million net from a follow-on offering.
- Accumulated deficit reached $514.10 million as of March 31, 2026.
Price Impact
More from AURA